S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.24
+1.56
+9.35%
TRAW · Traws Pharma, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Traws Pharma Inc (TRAW)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$0.38
-0.01
(-2.79%)
● At close: October 21 at 4:00:00 PM EDT
$0.36
-0.01
(-3.01%)
Overnight:
10:04:30 PM EDT
DAY'S RANGE
$0.38
$0.37
$0.38
52-WEEK RANGE
$0.38
$0.36
$3.23
What's happening
- TRAW is down 2.79% today, trading at $0.38. — Live quote
- It's trading within 3% of its 52-week low ($0.36). (Finnhub fundamentals)
- Volume today (1,378) is well below its 3-month average of 535,000. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.25 actual vs. $-0.34 estimated (+26.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 4
Sell 1
Strong sell 2
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TRAW
-66.66%
vs S&P 500
-79.44%
1-YEAR RETURN
TRAW
-87.73%
vs S&P 500
-102.29%
6-MONTH RETURN
TRAW
-68.87%
3-MONTH RETURN
TRAW
-37.90%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.25
Est. $-0.34
BEAT +26.9%
2026-04-26 (Q1 2026)
$-0.53
Est. $-0.75
BEAT +29.8%
2026-01-26 (Q4 2025)
$0.63
Est. $-1.25
BEAT +150.5%
2024-10-26 (Q4 2024)
$95.66
Est. $-9.74
BEAT +1082.0%
Valuation Measures & Ratios
Enterprise Value4$859.3K
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)2.02
Price / Book77.59
EV4 / Revenue0.30
EV4 / EBITDA—
Profit Margin-616.78%
Operating Margin-698.31%
Return on Equity (ROE8)-225.02%
Return on Assets (ROA9)-202.09%
Avg Volume (3M)535,000
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $15.7M | $24.0M | $21.9M | $12.2M | $23.9M |
| P/E | -1.04 | 2.53 | 2.69 | -0.11 | -0.21 |
| Price/Sales | — | — | — | 4.21 | 105.09 |
| EV/Revenue | — | — | — | 4.21 | 105.09 |
| EV/EBITDA | -1.02 | -1.38 | -1.15 | — | — |
| ROA | -131.11% | 116.55% | 65.40% | -710.81% | -603.85% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short690,685
Change from Prior Settlement+12.82%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -616.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -87.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TRAW
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.7M | $57.0K | $57.0K | $57.0K | $56.0K |
| Operating income | -$3.2M | -$6.9M | -$4.1M | -$1.2M | -$5.2M | -$8.5M | -$123.3M | -$5.2M |
| Net income | -$3.1M | -$7.1M | -$4.0M | -$915.0K | $21.5M | -$8.5M | -$123.1M | -$5.0M |
| EPS (diluted) | $-0.16 | $-0.53 | $-0.34 | $-0.11 | $2.09 | $-1.49 | $-20.52 | $-5.92 |
| EPS (basic) | $-0.16 | $-0.53 | $-0.34 | $-0.11 | $2.17 | $-1.49 | $-20.52 | $-5.92 |
| Operating margin | — | — | — | -$46 | -$9.1K | -$15.0K | -$216.4K | -$9.3K |
| Net margin | — | — | — | -$33 | $37.7K | -$14.9K | -$216.0K | -$8.9K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $11.5M | $8.2M | $10.6M | $12.4M | $15.6M | $19.1M | $25.0M | $8.9M |
| Total liabilities | $9.8M | $13.5M | $11.2M | $7.9M | $7.4M | $13.1M | $56.6M | $11.0M |
| Stockholders' equity | — | — | — | — | — | — | — | — |
| Total current assets | $9.0M | $5.7M | $8.0M | $9.6M | $15.4M | $18.9M | $25.0M | $8.9M |
| Total current liabilities | $9.7M | $13.2M | $11.1M | $7.9M | $7.4M | $10.4M | $11.5M | $8.3M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | $3.5M | $1.7M | $3.8M | $2.0M | $1.3M | $1.7M | $1.8M | $2.1M |
| Other current assets | $93.0K | $138.0K | $89.0K | $92.0K | $124.0K | $183.0K | $178.0K | $347.0K |
| Property, plant & equipment | $5.0K | $6.0K | $7.0K | $7.0K | $8.0K | $9.0K | $10.0K | $12.0K |
| Intangible assets | $2.4M | $2.5M | $2.5M | $2.6M | — | — | — | — |
| Other non-current assets | $1.0K | $1.0K | $104.0K | $240.0K | $244.0K | $198.0K | $1.0K | $1.0K |
| Accounts payable | $6.3M | $7.7M | $5.7M | $5.1M | $4.8M | $7.7M | $8.2M | $5.5M |
| Accrued liabilities | $3.4M | $5.5M | $5.5M | $2.8M | $2.6M | $2.5M | $3.1M | $2.6M |
| Deferred revenue (current) | — | — | — | — | — | $226.0K | $226.0K | $226.0K |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $152.0K | $101.0K | $90.0K | $71.0K | $71.0K | $50.0K | $36.0K | $30.0K |
| Retained earnings | -$650.1M | -$647.1M | -$640.0M | -$632.5M | -$628.6M | -$627.7M | -$649.2M | -$619.2M |
| Accumulated other comprehensive income (loss) | -$5.0K | -$2.0K | $6.0K | $6.0K | $9.0K | -$19.0K | -$42.0K | -$33.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.5M | -$2.6M | -$2.8M | -$4.0M | -$6.0M | -$5.4M | -$4.0M | -$11.5M |
| Investing cash flow | — | — | $0 | -$2.6M | — | — | $0 | $0 |
| Financing cash flow | $9.4M | $1.9M | $158.0K | -$62.0K | $3.1M | $13.0K | $20.0M | $0 |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $44.0K | $44.0K | $44.0K | $15.0K | $1.0K | $1.0K | $2.0K | $2.0K |
| Share-based compensation | $816.0K | $634.0K | $327.0K | $135.0K | $105.0K | $161.0K | $334.0K | $343.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$1.5M | $2.0M | $2.5M | $524.0K | -$3.0M | -$605.0K | $793.0K | -$702.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $226.0K | $226.0K | $226.0K | $226.0K |
| Operating income | -$17.9M | -$142.4M | -$20.3M | -$19.6M | -$16.5M |
| Net income | $9.2M | -$166.5M | -$18.9M | -$19.0M | -$16.2M |
| EPS (diluted) | $0.82 | $-35.21 | $-22.57 | $-0.91 | $-0.96 |
| EPS (basic) | $0.83 | $-35.21 | $-22.57 | $-0.91 | $-0.96 |
| Operating margin | -$641 | -$63.0K | -$9.0K | -$8.7K | -$7.3K |
| Net margin | $329 | -$73.7K | -$8.4K | -$8.4K | -$7.2K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $10.6M | $25.0M | $22.7M | $39.4M | $55.5M |
| Total liabilities | $11.2M | $56.6M | $12.0M | $11.1M | $9.4M |
| Stockholders' equity | — | — | — | — | — |
| Total current assets | $8.0M | $25.0M | $22.7M | $39.3M | $55.4M |
| Total current liabilities | $11.1M | $11.5M | $9.2M | $8.0M | $6.1M |
| Cash & equivalents | — | — | $20.6M | $38.5M | — |
| Accounts receivable | $3.8M | $1.8M | $18.0K | $29.0K | $28.0K |
| Other current assets | $89.0K | $178.0K | $401.0K | $40.0K | $35.0K |
| Property, plant & equipment | $7.0K | $10.0K | $22.0K | $24.0K | $38.0K |
| Intangible assets | $2.5M | — | — | — | — |
| Other non-current assets | $104.0K | $1.0K | $1.0K | $1.0K | $10.0K |
| Accounts payable | $5.7M | $8.2M | $5.6M | $3.9M | $2.8M |
| Accrued liabilities | $5.5M | $3.1M | $3.4M | $4.0M | $3.1M |
| Deferred revenue (current) | — | $226.0K | $226.0K | $226.0K | $226.0K |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $90.0K | $36.0K | $9.0K | $209.0K | $209.0K |
| Retained earnings | -$640.0M | -$649.2M | -$482.6M | -$463.7M | -$444.7M |
| Accumulated other comprehensive income (loss) | $6.0K | -$42.0K | -$23.0K | -$33.0K | -$14.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$18.2M | -$29.8M | -$17.9M | -$16.3M | -$19.5M |
| Investing cash flow | -$2.6M | -$3.6M | -$14.0K | — | — |
| Financing cash flow | $3.2M | $34.0M | — | — | $55.6M |
| Free cash flow | — | — | -$17.9M | — | — |
| Capital expenditures | — | — | $14.0K | — | — |
| Depreciation & amortization | $61.0K | $12.0K | $16.0K | $14.0K | $14.0K |
| Share-based compensation | $728.0K | $1.4M | $1.3M | $1.2M | $576.0K |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts payable | -$612.0K | $646.0K | $1.8M | $1.1M | -$2.1M |
| Purchases of investments | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TRAW as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-12 to 2026-04-16
Recent transactions
- Most recent: ORBIMED ADVISORS LLC (10% owner) — Open market purchase of 597,729 shares on 2026-04-16.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% owner | Open market purchase | 2026-04-16 | 597,729 |
| Parker Charles Nolan | Chief Financial Officer | Grant / award | 2025-12-12 | 15,393 |
| Leaman John Harold | Reporting person | Grant / award | 2025-12-12 | 4,058 |
| Clarke Trafford | Reporting person | Grant / award | 2025-12-12 | 6,157 |
| CAUTREELS WERNER | Reporting person | Grant / award | 2025-12-12 | 4,874 |
| Shoemaker Mary Teresa | Reporting person | Grant / award | 2025-12-12 | 6,157 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-16 | ORBIMED ADVISORS LLC | 10% owner | Open market purchase | 597,729 | $1.67 |
| 2025-12-12 | Parker Charles Nolan | Chief Financial Officer | Grant / award | 15,393 | $0.00 |
| 2025-12-12 | Leaman John Harold | Reporting person | Grant / award | 4,058 | $0.00 |
| 2025-12-12 | Clarke Trafford | Reporting person | Grant / award | 6,157 | $0.00 |
| 2025-12-12 | CAUTREELS WERNER | Reporting person | Grant / award | 4,874 | $0.00 |
| 2025-12-12 | Shoemaker Mary Teresa | Reporting person | Grant / award | 6,157 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:47 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-16 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-15 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-15 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-09 | View on SEC.gov → |
Recent news
Headlines about TRAW (Traws Pharma, Inc.). Links open the publisher — we don’t host full articles.
-
Form DEF 14A Traws Pharma Inc For: 20 October By Investing.com
Investing.com Canada · 2026-10-20 -
TRAW DEFA14A & SEC Filings
Yahoo Finance · 2026-10-20 -
Traws Pharma shares rise after Q2 loss comes in better than expected
Yahoo Finance · 2026-08-17 -
Traws Pharma GAAP EPS of -$0.16 beats by $0.06
Seeking Alpha · 2026-08-17 -
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Yahoo Finance · 2026-08-14 -
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Yahoo Finance · 2026-06-22 -
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls
Yahoo Finance · 2026-06-18 -
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
Yahoo Finance · 2026-06-15
No headlines in this category right now — try “All”.